QNCX

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

PRE 14A - Quince Therapeutics, Inc. (0001662774) (Filer)

S-8 - Quince Therapeutics, Inc. (0001662774) (Filer)

10-K - Quince Therapeutics, Inc. (0001662774) (Filer)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

NT 10-K - Quince Therapeutics, Inc. (0001662774) (Filer)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

Quince Therapeutics, Inc. (NASDAQ:QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Effective immediately upon the $5.5 million payment, Quince settled outstanding EIB debt obligations of approximately $16.4 million as of March 27, 2026. As a direct result of this $5.5 million payment, all of the company's obligations under

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

Quince Therapeutics, Inc. (NASDAQ:QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing, or other strategic transactions. LifeSci Capital will also act as the company's financial advisor in connection with any restructuring of the company's liabilities. The company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has appr

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

Citizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

Primary and key secondary endpoint did not achieve statistical significance eDSP was generally well tolerated with no clinically meaningful safety concerns identified Company to cease clinical development of eDSP; Intends to preserve cash and explore available options Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T). In the NEAT study, th

Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026. The objective of the data analysis was to describe the safety profile of long-term use of the company's lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in children with A-T who received eDSP for a minimum of two years. Key highlights re

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

144 - Quince Therapeutics, Inc. (0001662774) (Subject)